Alnylam Pharmaceuticals, Inc. ALNY Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-6,000

Price:

--
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-3,027

Price:

--
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,027

Price:

$174.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,000

Price:

$170.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,000

Price:

$169.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

6,000

Price:

$85.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

3,027

Price:

$77.40
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-13,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,941

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,000

Price:

$165.00

Filings by filing date

Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-6,000

Price:

--
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-3,027

Price:

--
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,027

Price:

$174.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,000

Price:

$170.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,000

Price:

$169.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

6,000

Price:

$85.00
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

3,027

Price:

$77.40
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-13,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,941

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Keating Laurie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,000

Price:

$165.00

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	675 W Kendall St CAMBRIDGE MA 02142-1168
Tel:	N/A
Website:	https://www.alnylam.com
IR:	See website

Key People

Michael W. Bonney Independent Chairman of the Board	Kasha Witkos Senior Vice President, Head of CEMEA	Yvonne L. Greenstreet President, Chief Operating Officer
John M. Maraganore Chief Executive Officer, Director	Jeffrey V. Poulton Chief Financial Officer, Executive Vice President	Akshay K. Vaishnaw President - Research and Development
Kelley Boucher Chief Human Resource Officer, Senior Vice President	Laurie Bartlett Keating Executive Vice President, Chief Legal Officer, Secretary	Kevin Fitzgerald Senior Vice President, Chief Scientific Officer
Salil Patel Senior Vice President, Head of Medical Affairs

Business Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.

Financial Overview

For the nine months ended 30 September 2020, AlnylamPharmaceuticals, Inc. revenues increased from $148.1M to$329.3M. Net loss increased 1% to $614.7M. Revenues reflectNet product revenues increase from $110.6M to $248.7M, Netrevenues from collaborations increase from $37.5M to$80.6M. Higher net loss reflects General and administrative- Balancing v increase of 33% to $213.6M (expense).

Employees:	1,323 as of Dec 31, 2019

Reporting Currency:	U.S. Dollars
Enterprise value:	$17,539M as of Sep 30, 2020
Annual revenue (TTM):	$400.97M as of Sep 30, 2020
EBITDA (TTM):	-$902.46M as of Sep 30, 2020
Net annual income (TTM):	-$890.93M as of Sep 30, 2020
Free cash flow (TTM):	-$775.30M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	116,180,768 as of Oct 30, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Alnylam Pharmaceuticals, Inc. (OQ:ALNY)